Please assess the completion status of the following clinical trial:

Trial Title: Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Adult patients with a documented diagnosis of SPMS with inflammatory disease activity who are going to be treated with Siponimod under routine medical care and in accordance with the Swiss label~3. Patient willing and able to complete the questionnaires~Exclusion Criteria:~1. Patients treated outside of the approved Swiss label for Siponimod~2. Prior treatment or already ongoing treatment with Siponimod~3. Use of investigational drugs during the study, OR within 3 months before enrollment, OR within 5 half-lives of investigational drug before enrollment, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer~4. Subjects who are not able to provide consent due to incapable judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siponimod (Type: None): Patients administered Siponimod as per Swiss label

Based on this trial design, predict the completion outcome and termination type (if applicable).